The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Bread and rolls sold in six states have been recalled over 'glass fragments,' according to the U.S. Food and Drug ...

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...

The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP”) patients was initiated in October 2024 and designed as a ...

A Blue Cross Blue Shield policy will force some patients to self-inject medicine, with potentially dangerous results.

Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and related product Synjardy (empagliflozin and metformin) have been cleared by the FDA for use in children aged 10 years and over ...

Previously, palovarotene failed a futility test in a pivotal trial and was also placed under a partial clinical hold by the FDA while it probed the drug's safety. Canada has now approved the drug ...

WHETHER we need a 3pm pick-me-up or we’re gearing up for a tough workout, many of us reach for an energy drink.  But before ...

Madison, a twelve-year-old from Illinois, visits a medical clinic every other week to get injections of Xolair, a powerful ...

How have the wild initial months of Donald Trump’s return to the White House landed on Washington? We asked the people who ...

The drug, which J&J will sell as Imaavy, was cleared by the FDA to treat adults and children 12 years of age or older who have an autoimmune condition known as generalized myasthenia gravis. The ...